OtherAccelerated Communication
3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”) Induces Fenfluramine-Like Proliferative Actions on Human Cardiac Valvular Interstitial Cells in Vitro
Vincent Setola, Sandra J. Hufeisen, K. Jane Grande-Allen, Ivan Vesely, Richard A. Glennon, Bruce Blough, Richard B. Rothman and Bryan L. Roth
Molecular Pharmacology June 2003, 63 (6) 1223-1229; DOI: https://doi.org/10.1124/mol.63.6.1223
Vincent Setola
Departments of Biochemistry (V.S., S.J.H., B.L.R.) and the National Institutes of Mental Health Psychoactive Drug Screening Program (S.J.H., B.L.R.), Case Western Reserve University School of Medicine, Cleveland, Ohio; Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio, (K.J.G.-A., I.V.); Department of Medicinal Chemistry, Virginia Commonwealth University, Richmond, Virginia (R.A.G.); Chemistry and Life Sciences Group, Research Triangle Institute International, Research Triangle Park, North Carolina (B.B.); and Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland (R.B.R.)
Sandra J. Hufeisen
Departments of Biochemistry (V.S., S.J.H., B.L.R.) and the National Institutes of Mental Health Psychoactive Drug Screening Program (S.J.H., B.L.R.), Case Western Reserve University School of Medicine, Cleveland, Ohio; Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio, (K.J.G.-A., I.V.); Department of Medicinal Chemistry, Virginia Commonwealth University, Richmond, Virginia (R.A.G.); Chemistry and Life Sciences Group, Research Triangle Institute International, Research Triangle Park, North Carolina (B.B.); and Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland (R.B.R.)
K. Jane Grande-Allen
Departments of Biochemistry (V.S., S.J.H., B.L.R.) and the National Institutes of Mental Health Psychoactive Drug Screening Program (S.J.H., B.L.R.), Case Western Reserve University School of Medicine, Cleveland, Ohio; Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio, (K.J.G.-A., I.V.); Department of Medicinal Chemistry, Virginia Commonwealth University, Richmond, Virginia (R.A.G.); Chemistry and Life Sciences Group, Research Triangle Institute International, Research Triangle Park, North Carolina (B.B.); and Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland (R.B.R.)
Ivan Vesely
Departments of Biochemistry (V.S., S.J.H., B.L.R.) and the National Institutes of Mental Health Psychoactive Drug Screening Program (S.J.H., B.L.R.), Case Western Reserve University School of Medicine, Cleveland, Ohio; Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio, (K.J.G.-A., I.V.); Department of Medicinal Chemistry, Virginia Commonwealth University, Richmond, Virginia (R.A.G.); Chemistry and Life Sciences Group, Research Triangle Institute International, Research Triangle Park, North Carolina (B.B.); and Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland (R.B.R.)
Richard A. Glennon
Departments of Biochemistry (V.S., S.J.H., B.L.R.) and the National Institutes of Mental Health Psychoactive Drug Screening Program (S.J.H., B.L.R.), Case Western Reserve University School of Medicine, Cleveland, Ohio; Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio, (K.J.G.-A., I.V.); Department of Medicinal Chemistry, Virginia Commonwealth University, Richmond, Virginia (R.A.G.); Chemistry and Life Sciences Group, Research Triangle Institute International, Research Triangle Park, North Carolina (B.B.); and Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland (R.B.R.)
Bruce Blough
Departments of Biochemistry (V.S., S.J.H., B.L.R.) and the National Institutes of Mental Health Psychoactive Drug Screening Program (S.J.H., B.L.R.), Case Western Reserve University School of Medicine, Cleveland, Ohio; Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio, (K.J.G.-A., I.V.); Department of Medicinal Chemistry, Virginia Commonwealth University, Richmond, Virginia (R.A.G.); Chemistry and Life Sciences Group, Research Triangle Institute International, Research Triangle Park, North Carolina (B.B.); and Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland (R.B.R.)
Richard B. Rothman
Departments of Biochemistry (V.S., S.J.H., B.L.R.) and the National Institutes of Mental Health Psychoactive Drug Screening Program (S.J.H., B.L.R.), Case Western Reserve University School of Medicine, Cleveland, Ohio; Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio, (K.J.G.-A., I.V.); Department of Medicinal Chemistry, Virginia Commonwealth University, Richmond, Virginia (R.A.G.); Chemistry and Life Sciences Group, Research Triangle Institute International, Research Triangle Park, North Carolina (B.B.); and Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland (R.B.R.)
Bryan L. Roth
Departments of Biochemistry (V.S., S.J.H., B.L.R.) and the National Institutes of Mental Health Psychoactive Drug Screening Program (S.J.H., B.L.R.), Case Western Reserve University School of Medicine, Cleveland, Ohio; Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio, (K.J.G.-A., I.V.); Department of Medicinal Chemistry, Virginia Commonwealth University, Richmond, Virginia (R.A.G.); Chemistry and Life Sciences Group, Research Triangle Institute International, Research Triangle Park, North Carolina (B.B.); and Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland (R.B.R.)
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
OtherAccelerated Communication
3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”) Induces Fenfluramine-Like Proliferative Actions on Human Cardiac Valvular Interstitial Cells in Vitro
Vincent Setola, Sandra J. Hufeisen, K. Jane Grande-Allen, Ivan Vesely, Richard A. Glennon, Bruce Blough, Richard B. Rothman and Bryan L. Roth
Molecular Pharmacology June 1, 2003, 63 (6) 1223-1229; DOI: https://doi.org/10.1124/mol.63.6.1223
OtherAccelerated Communication
3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”) Induces Fenfluramine-Like Proliferative Actions on Human Cardiac Valvular Interstitial Cells in Vitro
Vincent Setola, Sandra J. Hufeisen, K. Jane Grande-Allen, Ivan Vesely, Richard A. Glennon, Bruce Blough, Richard B. Rothman and Bryan L. Roth
Molecular Pharmacology June 1, 2003, 63 (6) 1223-1229; DOI: https://doi.org/10.1124/mol.63.6.1223
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement